|Mr. Michael S. Poirier||Chairman, CEO & Pres||N/A||N/A||1956|
|Mr. Christopher L. Lotz||VP of Fin. & CFO||N/A||N/A||1965|
|Mr. Shishir K. Sinha||VP of Operations||N/A||N/A||1967|
|Dr. Wajdi Abdul-Ahad||VP of R&D and Chief Scientific Officer||N/A||N/A||1953|
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.